March 2025

Newswire

[ March 13, 2025 ] FDA Issues Clearance for ReWalk 7 Exoskeleton (NASDAQ: LFWD) Newsmakers
[ March 13, 2025 ] ImmunoPrecise (NASDAQ: IPA)Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics. Newsmakers
[ March 13, 2025 ] “Pure Play on US Drone Market” Unusual Machines (NYSE: UMAC) CEO Interview with Allan Evans Aerospace & Defense
[ March 6, 2025 ] Plus Therapeutics (NASDAQ: PSTV) Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer Newsmakers
[ March 3, 2025 ] BioXcel Therapeutics (NASDAQ: BTAI) Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer’s Dementia Newsmakers
[ February 24, 2025 ] PepGen (NASDAQ: PEPG) Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights Newsmakers
[ February 18, 2025 ] ScanTech AI (NASDAQ: STAI) Announces Initiative to Combat Contraband in Correctional Facilities Across the Americas Newsmakers
[ February 18, 2025 ] ProPhase Labs (NASDAQ: PRPH) hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports Newsmakers
[ February 5, 2025 ] Cumberland Pharmaceuticals (NASDAQ: CPIX) Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease Newsmakers
[ February 5, 2025 ] Pasithea Therapeutics (NASDAQ: KTTA) Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer Newsmakers

FDA Issues Clearance for ReWalk 7 Exoskeleton (NASDAQ: LFWD)

March 13, 2025 admin Comments Off

Seventh Generation of Industry-Leading Exoskeleton Includes New and Enhanced Features for Individuals with Spinal Cord Injury MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 13, 2025 — Lifeward Ltd., (NASDAQ: LFWD) (“Lifeward” or the “Company”), a […]

ImmunoPrecise (NASDAQ: IPA)Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.

March 13, 2025 admin Comments Off

Programs to be Driven Through Patented AI Technology and Advanced Proprietary B Cell Platforms Partnership advances next-generation ADCs and bispecific antibodies to address unmet medical needs AUSTIN, Texas, March 13, 2025—ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: […]

“Pure Play on US Drone Market” Unusual Machines (NYSE: UMAC) CEO Interview with Allan Evans

March 13, 2025 admin Comments Off

Unusual Machines (NYSE: UMAC) CEO Interview with Allan Evans Unusual Machines (NYSE: UMAC) CEO Allan Evans discusses UMAC growth strategy in multi-billion dollar US drone market. While the drone market is booming, Evans sees the […]

Plus Therapeutics (NASDAQ: PSTV) Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

March 6, 2025 admin Comments Off

HOUSTON, March 06, 2025 — Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announces that the […]

BioXcel Therapeutics (NASDAQ: BTAI) Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer’s Dementia

March 3, 2025 admin Comments Off

FDA concludes site inspection is closed under 21 C.F.R.20.64(d)(3); Voluntary Action Indicated Company believes this further supports reliability of data from TRANQUILITY II trial of BXCL501 NEW HAVEN, Conn., March 03, 2025 — BioXcel Therapeutics, […]